- Home
- MKZR vs ONCO Comparison
MKZR vs ONCO Comparison
Compare MKZR & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKZR | ONCO |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.0M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MKZR | ONCO |
|---|---|---|
| Price | $1.14 | $0.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.8K | ★ 5.0M |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.87 | 22.80 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,007,414.00 | $815,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.83 | $0.09 |
| 52 Week High | $5.60 | $798.00 |
Technical Indicators
Market Signals| Indicator | MKZR | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 34.75 | 33.34 |
| Support Level | $0.83 | $0.09 |
| Resistance Level | $1.55 | $1.02 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 24.08 | 7.32 |
Price Performance
Historical ComparisonAbout MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a real estate investment manager and a real estate investment trust (REIT) engaged in discounted real estate securities and asset management. The Company operates through two primary operating and reportable segments: commercial, which generates maximum revenue, and residential. These segments include activities related to acquiring, owning, developing, and managing income-producing real estate properties. Its properties are geographically diversified throughout the United States.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.